Last reviewed · How we verify
Lanthanum Carbonate Chewable Tablet
Lanthanum Carbonate Chewable Tablet is a Phosphate binder Small molecule drug developed by SIGA Technologies. It is currently FDA-approved for Hyperphosphatemia in patients with chronic kidney disease on dialysis. Also known as: Fosrenol.
Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels.
Lanthanum carbonate binds phosphate in the gastrointestinal tract, reducing serum phosphate levels in patients with chronic kidney disease. Used for Hyperphosphatemia in patients with chronic kidney disease on dialysis, Hyperphosphatemia in patients with chronic kidney disease not on dialysis.
At a glance
| Generic name | Lanthanum Carbonate Chewable Tablet |
|---|---|
| Also known as | Fosrenol |
| Sponsor | SIGA Technologies |
| Drug class | Phosphate binder |
| Target | Dietary phosphate (non-receptor mechanism) |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Mechanism of action
Lanthanum is a rare earth element that acts as a phosphate binder in the GI tract. It dissociates to release lanthanum ions, which form highly insoluble lanthanum phosphate complexes with dietary phosphate. These complexes cannot be absorbed and are excreted in stool, effectively reducing the bioavailability of phosphate and lowering serum phosphate concentrations in patients with hyperphosphatemia.
Approved indications
- Hyperphosphatemia in patients with chronic kidney disease on dialysis
Common side effects
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Abdominal pain
Key clinical trials
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (PHASE4)
- Head to Head Study Against Sevelamer Hydrochloride (PHASE3)
- Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults (PHASE1)
- Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD (PHASE2)
- Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients (PHASE2)
- Fosrenol Post-marketing Surveillance for Hemodialysis in Japan
- Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan
- Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lanthanum Carbonate Chewable Tablet CI brief — competitive landscape report
- Lanthanum Carbonate Chewable Tablet updates RSS · CI watch RSS
- SIGA Technologies portfolio CI
Frequently asked questions about Lanthanum Carbonate Chewable Tablet
What is Lanthanum Carbonate Chewable Tablet?
How does Lanthanum Carbonate Chewable Tablet work?
What is Lanthanum Carbonate Chewable Tablet used for?
Who makes Lanthanum Carbonate Chewable Tablet?
Is Lanthanum Carbonate Chewable Tablet also known as anything else?
What drug class is Lanthanum Carbonate Chewable Tablet in?
What development phase is Lanthanum Carbonate Chewable Tablet in?
What are the side effects of Lanthanum Carbonate Chewable Tablet?
What does Lanthanum Carbonate Chewable Tablet target?
Related
- Drug class: All Phosphate binder drugs
- Target: All drugs targeting Dietary phosphate (non-receptor mechanism)
- Manufacturer: SIGA Technologies — full pipeline
- Therapeutic area: All drugs in Nephrology
- Indication: Drugs for Hyperphosphatemia in patients with chronic kidney disease on dialysis
- Also known as: Fosrenol
- Compare: Lanthanum Carbonate Chewable Tablet vs similar drugs
- Pricing: Lanthanum Carbonate Chewable Tablet cost, discount & access